FDG PET/CT for Staging and Restaging Malignant Mesothelioma

被引:6
作者
Lopci, Egesta [1 ,4 ]
Castello, Angelo [2 ]
Mansi, Luigi [3 ]
机构
[1] IRCCS Humanitas Res Hosp, Nucl Med Unit, Milan, Italy
[2] Fdn IRCCS CaGranda, Nucl Med Unit, Milan, Italy
[3] Interuniv Res Ctr Sustainable Dev CIRPS, Rome, Italy
[4] IRCCS Humanitas Res Hosp, Nucl Med Unit, Via Manzoni 56, I-20089 Rozzano, Lombardy, Italy
关键词
POSITRON-EMISSION-TOMOGRAPHY; RESPONSE EVALUATION CRITERIA; FORTHCOMING 8TH EDITION; PLEURAL MESOTHELIOMA; PERITONEAL MESOTHELIOMA; COMPUTED-TOMOGRAPHY; TALC PLEURODESIS; TNM CLASSIFICATION; IASLC MESOTHELIOMA; PROGNOSTIC-FACTORS;
D O I
10.1053/j.semnuclmed.2022.07.005
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Malignant mesothelioma is an aggressive tumor originating from the mesothelial cells and presenting in general with a very poor prognosis. The pleural localization represents the prevailing disease site, while peritoneal involvement is commonly rare. The WHO classifies mesotheliomas into epithelioid, biphasic, and sarcomatoid histotypes, having diverse out-come with the sarcomatoid or biphasic forms showing the poorest prognosis. Given the peculiar rind-like pattern of growth, mesothelioma assessment is rather challenging for medical imagers. Conventional imaging is principally based on contrast-enhanced CT, while the role of functional and metabolic imaging is regarded as complementary. By focus-ing essentially on the staging and restaging role of [18F]FDG PET/CT in malignant mesothe-liomas, the present review will summarize the available data present in literature and provide some hints on alternative imaging and future perspectives. Given the prevailing incidence of pleural disease, the majority of the information will be addressed on malignant pleural mesothelioma, although a summary of principal characteristics and imaging findings in patients with peritoneal mesothelioma will be also provided. Semin Nucl Med 52:806-815 (c) 2022 Elsevier Inc. All rights reserved.
引用
收藏
页码:806 / 815
页数:10
相关论文
共 121 条
  • [1] Clinical implications of 18F-fluorodeoxyglucose positron emission tomography/computed tomography at delayed phase for diagnosis and prognosis of malignant pleural mesothelioma
    Abe, Yoshiyuki
    Tamura, Katsumi
    Sakata, Ikuko
    Ishida, Jiro
    Ozeki, Yuichi
    Tamura, Atsuhisa
    Uematsu, Kazutsugu
    Sakai, Hiroshi
    Goya, Tomoyuki
    Kanazawa, Minoru
    Machida, Kikuo
    [J]. ONCOLOGY REPORTS, 2012, 27 (02) : 333 - 338
  • [2] False positive 18F-FDG-PET/CT in a patient after talc pleurodesis
    Ahmadzadehfar, Hojjat
    Palmedo, Holger
    Strunk, Holger
    Biersack, Hans-Juergen
    Habibi, Elham
    Ezziddin, Samer
    [J]. LUNG CANCER, 2007, 58 (03) : 418 - 421
  • [3] AISNER J, 1995, CHEST, V108, P1122
  • [4] Current Management and Future Opportunities for Peritoneal Metastases: Peritoneal Mesothelioma
    Alexander, H. Richard, Jr.
    Li, Claire Yue
    Kennedy, Timothy J.
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2018, 25 (08) : 2159 - 2164
  • [5] Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial
    Alley, Evan W.
    Lopez, Juanita
    Santoro, Armando
    Morosky, Anne
    Saraf, Sanatan
    Piperdi, Bilal
    van Brummelen, Emilie
    [J]. LANCET ONCOLOGY, 2017, 18 (05) : 623 - 630
  • [6] Ambrosini V, 2005, NUCL MED REV, V8, P111
  • [7] Baldini EH, 1997, ANN THORAC SURG, V63, P334
  • [8] Metabolic imaging of malignant pleural mesothelioma with fluorodeoxyglucose positron emission tomography
    Bénard, F
    Sterman, D
    Smith, RJ
    Kaiser, LR
    Albelda, SM
    Alavi, A
    [J]. CHEST, 1998, 114 (03) : 713 - 722
  • [9] The eighth TNM classification for malignant pleural mesothelioma
    Berzenji, Lawek
    Van Schil, Paul E.
    Carp, Laurens
    [J]. TRANSLATIONAL LUNG CANCER RESEARCH, 2018, 7 (05) : 543 - 549
  • [10] Bianchi C, 1997, EUR J CANCER PREV, V6, P162